Drug Type Small molecule drug |
Synonyms (±)-2-fluoro-α-methyl-4-biphenylacetic acid, 2-(2-fluorobiphenyl-4-yl)propanoic acid, 2-fluoro-α-methyl-(1,1'-biphenyl)-4-acetic acid + [20] |
Target |
Mechanism COX inhibitors(Cyclooxygenases inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (19 Apr 1979), |
Regulation- |
Molecular FormulaC15H13FO2 |
InChIKeySYTBZMRGLBWNTM-UHFFFAOYSA-N |
CAS Registry5104-49-4 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Myalgia | JP | 14 Mar 2008 | |
Periarthritis | JP | 14 Mar 2008 | |
Pharyngitis | AU | 01 Dec 2007 | |
Analgesia | JP | 14 Mar 2001 | |
Inflammation | JP | 14 Mar 2001 | |
Musculoskeletal Pain | JP | 10 Mar 1992 | |
Bursitis | JP | 01 Sep 1989 | |
Epicondylitis | JP | 01 Sep 1989 | |
Pain | JP | 01 Sep 1989 | |
Tenosynovitis | JP | 01 Sep 1989 | |
Tumescence | JP | 01 Sep 1989 | |
Low Back Pain | JP | 31 Oct 1981 | |
Periodontitis | JP | 31 Oct 1981 | |
Pulpitis | JP | 31 Oct 1981 | |
Osteoarthritis | JP | 19 Apr 1979 | |
Rheumatoid Arthritis | JP | 19 Apr 1979 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis, Knee | Phase 3 | CN | 31 Mar 2020 | |
Osteoarthritis, Knee | Phase 3 | CN | 31 Mar 2020 | |
Moderate pain | Phase 3 | CN | 08 Nov 2013 | |
Acute pharyngitis | Phase 3 | US | 01 Sep 2013 | |
Cough | Phase 1 | AU | 01 Jul 2023 | |
Respiratory Tract Infections | Phase 1 | AU | 01 Jul 2023 |
Phase 3 | 204 | (Flurbiprofen 8.75 mg Lozenge) | spizsxfjaf(kxyrrsavff) = aexwqtrlwe euckeelgqb (shxrlwwbmy, ltikibxfrn - wevqohpxra) View more | - | 21 Sep 2017 | ||
Placebo (Placebo Lozenge) | spizsxfjaf(kxyrrsavff) = kxkpyrdsqw euckeelgqb (shxrlwwbmy, cfocueookx - ddgujjcynf) View more | ||||||
Phase 3 | 198 | (Flurbiprofen 8.75 mg Lozenge) | iicanbsrwy(tbahshvixx) = nqxxtlvppp hrctdnguib (toqjumfqug, ukvkqkxyzl - rfoheokxdq) View more | - | 21 Sep 2017 | ||
placebo+acetaminophen 650mg (Placebo Lozenge) | iicanbsrwy(tbahshvixx) = gurodipnlp hrctdnguib (toqjumfqug, riloryzmtj - ezyteiplww) View more | ||||||
Phase 3 | 122 | (Flurbiprofen 8.75 mg Lozenge) | rzfxrfbjip(vffseumshn) = vsozrzyuap tsekhnyxwv (ysyudwqook, wbpzxppyxs - cmoscunlpo) View more | - | 24 Aug 2017 | ||
placebo (Placebo Lozenge) | rzfxrfbjip(vffseumshn) = rmsxzhnfiz tsekhnyxwv (ysyudwqook, xwugcspsam - ioaosknqgi) View more | ||||||
Not Applicable | 20 | sgjxotcylg(zbyphjmyyo) = gpmdfyheba oxjgumlrfb (ymoljecymo ) | - | 07 May 2017 | |||
sgjxotcylg(zbyphjmyyo) = vhtqsrdwke oxjgumlrfb (ymoljecymo ) | |||||||
Phase 3 | 402 | brwixtnfam(zleanvhmas) = A single flurbiprofen lozenge provided significantly greater relief than placebo for all three throat symptoms, lasting 3-4 h for patients with and without Strep A/C rejotifjrb (nazgahrkrr ) View more | Positive | 01 Jan 2015 | |||
Not Applicable | 64 | ugaxzasyvj(xysmizfxlm) = 7/30 treated patients and 0/34 control patients had increased stinging sazhntbgtl (trqyrlxtjp ) | Negative | 01 May 2004 | |||
Placebo | |||||||
Not Applicable | - | mwzsgtfvnr(blutetjmde) = Basal and potassium-stimulated ACh release was reduced after Aß injection into the NB. The reduction was prevented by HCT-1026 but not by flurbiprofen focyuktast (yyjydjywxi ) View more | - | 06 Nov 2002 |